Although the efficacy of the regimens except RET-TKIs is limited, they are still a reasonable choice for NSCLC patients with RET fusion, especially under the prelude of the RET-TKI application, meaning that issues such as not only price but also accessibility may turn many patients away (6). The gene discussed is RET; the disease is non-small cell lung carcinoma.